Regulatory and Commercial Impact Analysis of ANMAT Regulations 2025–2026

1. GENERAL CONTEXT OF REGULATORY CHANGES

Strategic Orientation

The regulations issued by ANMAT between October 2025 and February 2026 respond to a clear strategy of modernization and administrative simplification of the regulatory framework for medical devices. This change represents a paradigm shift from a model of rigorous ex-ante control to a model of regulatory trust with strengthened ex-post control.

International Alignment

Argentina is positioning itself as a regional reference regulatory authority, having been designated as such in 2017 and incorporated as a regulatory member of the ICH (International Council for Harmonisation) in 2024. This context explains the adoption of international standards such as ICH E6 R3 and the recognition of certifications from countries with highly recognized technical-sanitary standards.

2. SPECIFIC REGULATORY IMPACT BY PROVISION

2.1 Provision 224/2026: Import of Used Medical Products

Fundamental Regulatory Change:

The repeal of Provision 806/2007 and the elimination of the requirement for the Certificate of Import of Used Goods (CIBU) represents a selective deregulation that maintains health protection without hindering trade.

Regulatory Impact:

• Reduction of administrative barriers: Elimination of a prior procedure that slowed down imports
• Flexibilization of options: Allows importation by end-users, not just by authorized companies
• Maintenance of standards: Continues to require reconditioning by authorized or equivalent establishments
• Risk differentiation: “Single-use” products remain prohibited, prioritizing safety

Commercial Impact:

• Access to modern equipment: Small health centers can access better quality equipment at reduced prices
• Price competition: Importers can offer more economical alternatives
• Market expansion: New players (end-users) can participate in importation
• Cost reduction: Elimination of CIBU reduces administrative costs and import times
• Commercial risks: Potential for unfair competition if reconditioning is not properly verified

2.2 Provision 236/2026: Simplified Notification System

Fundamental Regulatory Change:

Implementation of a notification system by sworn declaration that recognizes the regulatory equivalence of reference countries, eliminating duplicate local tests.

Regulatory Impact:

• Recognition of equivalence: Acceptance of Free Sale Certificates from countries with recognized standards
• Reduction of duplication: Avoids unnecessary tests already carried out in equivalent jurisdictions
• Streamlining of procedures: Prior notification without local tests accelerates commercialization
• Ex-post control: Strengthening of post-market surveillance
• Primary responsibility: Manufacturers and importers assume responsibility for quality, safety, and efficacy

Commercial Impact:

• Time reduction: Faster commercialization of products (weeks vs. months)
• Cost reduction: Elimination of local tests reduces initial investment
• Access to innovation: Innovative products reach the Argentine market more quickly
• Regional competitiveness: Argentina aligns with standards of developed countries
• Portfolio expansion: Companies can launch more products in less time
• Risks: Greater dependence on foreign certifications; requires ex-post surveillance capacity

2.3 Provision 8799/2025: Simplified Authorization of Manufacturers and Importers

Fundamental Regulatory Change:

Creation of an optional regime for authorization by sworn declaration for low-risk products, parallel to traditional procedures.

Regulatory Impact:

• Procedural flexibility: Companies can choose between the simplified or traditional regime
• Reduction of requirements: Sworn declaration with no expiration date vs. formal procedure
• Maintenance of standards: Continues to require compliance with Good Manufacturing Practices
• Regular inspections: Ex-post control through compliance audits
• Corporate responsibility: Sworn declaration implies legal responsibility of the declarant

Commercial Impact:

• Facilitation of entry: New companies can be authorized more quickly
• Reduction of administrative costs: Simplified procedure reduces processing expenses
• Formalization of informal actors: Potential to formalize small producers
• Democratization of the market: Favors SMEs and entrepreneurship
• Risks: Possible reduction of control if inspections are not sufficient; requires surveillance capacity

2.4 Provision 7516/2025: Internationalized Good Clinical Practices

Fundamental Regulatory Change:

Adoption of international standards ICH E6 R3 for clinical studies, decentralizing authorities and streamlining processes.

Regulatory Impact:

• International harmonization: Adoption of ICH E6 R3 guide aligns Argentina with global standards
• Decentralization: Incorporates jurisdictional authorities in the evaluation of studies
• Streamlining: Faster processes through decentralization
• Subject protection: Strengthens safety and traceability requirements
• International participation: Facilitates multicenter clinical studies

Commercial Impact:

• Investment attraction: International pharmaceutical companies can conduct studies in Argentina
• Job creation: Clinical research centers require specialized personnel
• Knowledge transfer: Participation in international research
• Scientific competitiveness: Argentina positions itself as a regional research center
• Costs: Compliance with international standards requires investment in training

3. INTEGRATED COMMERCIAL IMPACT

3.1 Cost and Time Reduction

3.2 Accessibility to Medical Products

Positive Impact:

• More accessible medical equipment for small health centers
• Innovative products arrive more quickly
• More competitive prices due to cost reduction
• Greater variety of options available

Potential Risks:

• Need to strengthen ex-post surveillance capacity
• Possible entry of lower quality products if controls are not effective
• Dependence on foreign certifications requires validation

3.3 Business Competitiveness

Favored:

• Importers of low-risk products
• Small manufacturers of medical devices
• Distributors of reconditioned used equipment
• Clinical research centers

Challenged:

• Local testing laboratories (reduced demand)
• Companies with models based on regulatory barriers
• Importers of high-risk products (no changes)

4. SANITARY AND PUBLIC HEALTH IMPACT

4.1 Expected Benefits

• Equitable access: Quality medical equipment at affordable prices
• Timely diagnosis: Faster availability of diagnostic equipment
• Clinical research: Facilitates studies that generate local evidence
• Subject protection: International standards in clinical research

4.2 Risks to Mitigate

• Product quality: Requires effective ex-post surveillance
• Patient safety: Reconditioned products must meet standards
• Trazability: Information systems must track imported products
• Regulatory capacity: ANMAT requires resources for inspections and audits

5. SYNTHESIS OF GENERAL COMMERCIAL IMPACT

Commercial Opportunities

• Reduction of entry barriers
• Acceleration of commercialization
• Cost reduction
• Access to innovation
• Participation in research

Commercial Challenges

• Intensification of competition
• Price pressure
• Variable quality
• Dependence on certifications
• Surveillance capacity

6. CONCLUSION

The 2025-2026 regulations represent a paradigm shift towards a more agile and efficient regulatory model, aligned with international standards. The commercial impact is potentially very positive for access to quality medical products, but requires strengthening of ex-post surveillance capabilities to maintain health standards. Companies that adapt quickly to these changes will have significant competitive advantages.